UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number 001-39678 SANARA MEDTECH INC. (Exact name of Registrant as specified in its charter) Texas 59-2219994 (State or other jurisdiction of (I ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Sanara MedTech Inc. (SMTI) came out with quarterly earnings of $0.04 per share, missing the Zacks Consensus Estimate of $0.11 per share. This compares to a loss of $0.18 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -63.64%. A quarter ago, it was expected that this company would post a loss of $0.24 per share when it actually produced earnings of $0.09, delivering a surprise of +137.5%.Over the last four quarters, the compan ...

Sanara MedTech (NasdaqCM:SMTI) Q4 2025 Earnings call March 24, 2026 08:00 AM ET Company ParticipantsElizabeth Taylor - CFOSeth Yon - President and CEOConference Call ParticipantsEduardo Rafael Martinez-Montes - Biotech Equity Research AnalystOperatorWelcome to the Sanara MedTech fourth quarter and full year 2025 earnings conference call. Please note that this conference call is being recorded and a replay will be available on the investor relations page of the company's website shortly. The company issued i ...

Sanara MedTech (NasdaqCM:SMTI) Q4 2025 Earnings call March 24, 2026 08:00 AM ET Company ParticipantsEduardo Rafael Martinez-Montes - Biotechnology Equity Research AssociateElizabeth Taylor - CFOSeth Yon - President and CEOOperatorWelcome to the Sanara MedTech fourth quarter and full year 2025 earnings conference call. Please note that this conference call is being recorded and a replay will be available on the investor relations page of the company's website shortly. The company issued its earnings release ...

Sanara MedTech (NasdaqCM:SMTI) Q4 2025 Earnings call March 24, 2026 08:00 AM ET Company ParticipantsEduardo Martinez-Montes - Biotechnology Equity Research AssociateElizabeth Taylor - CFOSeth Yon - President and CEOOperatorWelcome to the Sanara MedTech fourth quarter and full year 2025 earnings conference call. Please note that this conference call is being recorded and a replay will be available on the investor relations page of the company's website shortly. The company issued its earnings release earlier ...

Sanara MedTech (NasdaqCM:SMTI) Q4 2025 Earnings call March 24, 2026 08:00 AM ET Company ParticipantsElizabeth Taylor - CFOSeth Yon - President and CEOConference Call ParticipantsEduardo Rafael Martinez-Montes - Biotech Equity Research AnalystOperatorWelcome to the Sanara MedTech fourth quarter and full year 2025 earnings conference call. Please note that this conference call is being recorded and a replay will be available on the investor relations page of the company's website shortly. The company issued i ...

Sanara MedTech (NasdaqCM:SMTI) Q4 2025 Earnings call March 24, 2026 08:00 AM ET Speaker2Welcome to the Sanara MedTech fourth quarter and full year 2025 earnings conference call. Please note that this conference call is being recorded and a replay will be available on the investor relations page of the company's website shortly. The company issued its earnings release earlier today. Before we begin, I would like to remind everyone that certain statements on today's call will include forward-looking statement ...

FORT WORTH, TX, March 24, 2026 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market, today reported its financial results for the fourth quarter and full year ended December 31, 2025, and reaffirmed its financial guidance for the full year ending December 31, 2026. Fourth Qua ...

Core Insights - The study published in the Journal of Medical Economics highlights the cost savings and improved health outcomes associated with CellerateRX® when used as an adjunct to standard care for high-risk spinal surgery patients [1][2]. Economic and Clinical Evaluation - Researchers utilized economic modeling to assess clinical outcomes and direct medical costs for high-comorbidity patients undergoing complex spinal surgeries, comparing two treatment groups: one receiving CellerateRX and the other receiving standard care alone [2][3]. - The study measured postoperative complications, hospital readmissions, and surgical revisions over a one-year period, with clinical efficacy evaluated in quality-adjusted life years (QALYs) and costs in 2025 U.S. dollars [3]. Cost-Effectiveness Findings - The CellerateRX treatment group demonstrated a cost savings of $3,852 per patient and a QALY gain of 0.007, resulting in a net monetary benefit of $4,542 [4]. - Major contributors to cost savings included avoidance of hospital readmissions ($2,238) and surgical revisions ($835) [4]. - In probabilistic analyses, CellerateRX showed a dominant cost-effectiveness profile in over 99% of clinical variability simulations compared to standard care [4]. Conclusion and Implications - The findings support CellerateRX as a value-enhancing component in the management of surgical wounds for high-risk spinal surgery patients, promoting both improved health outcomes and cost savings [5].